CaryHealth Clair vs OpenEvidence
A small bounded reference product against the most scrutinised one in the category. Clair answers from a named corpus of public drug, trial and guideline sources with every response linked back to its references, and it describes its retrieval technique more concretely than several better resourced peers. OpenEvidence reaches current primary literature through partnerships with major journals and a systematic review publisher, is free to verified United States clinicians, and carries eleven independent studies evaluating it, which is more external scrutiny than anything else here. For most clinicians OpenEvidence is the stronger product and its advertising funded model is the thing to weigh. Clair's value is that its corpus is bounded and stated, which makes what it does not cover knowable.
- The corpus is bounded and named over public drug, trial and guideline sources, with every response linked back to its references and source routing described.
- It names more technique than several better graded peers, describing retrieval and grounding rather than gesturing at reasoning.
- A published interface means another product can embed the reference layer rather than adopting the application.
- The independent literature is the deepest in this category, with a systematic review identifying eleven studies evaluating it across two years.
- Named partnerships with major journals and a systematic review publisher supply current primary literature rather than a static corpus.
- It is free to verified United States clinicians with enterprise record system embedding documented at named health systems.
Side by Side
| Axis | C CaryHealth Clair |
O OpenEvidence |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
OpenEvidence is funded by pharmaceutical and medical device advertising displayed alongside clinical answers, governed by a published advertising policy that is the artifact to read before accepting the arrangement in a clinical setting. Clair publishes no security certification, accuracy measurement or error rate, and its commercial disclosure takes a distinctive form that a buyer should read carefully rather than assume. Neither publishes a mechanism for detecting a superseded source, which is the failure mode of any curated corpus.